Literature DB >> 12507762

Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat.

Andreas Geier1, Christoph G Dietrich, Thomas Gerloff, Jenny Haendly, Gerd A Kullak-Ublick, Bruno Stieger, Peter J Meier, Siegfried Matern, Carsten Gartung.   

Abstract

BACKGROUND/AIMS: Estrogen-mediated cholestasis is an important clinical entity, but its molecular pathophysiology is still not fully understood. Impaired sodium-dependent uptake of bile acids has been associated with diminished expression of a basolateral Na(+)/bile acid cotransporter (Ntcp), whereas sodium-independent uptake is maintained despite a down-regulation of the organic anion transporter Oatp1. Thus, expression of the two other rat Oatps (Oatps2 and -4) was determined in estrogen-induced cholestasis. In addition, known transactivators of Oatp2 and Ntcp were studied to further characterize transcriptional regulation of these transporter genes.
METHODS: Hepatic protein and mRNA expression of various Oatps (1, 2, 4) in comparison to Ntcp were analyzed after 0.5, 1, 3 and 5 days of ethinylestradiol (EE) treatment (5 mg/kg) in rats. Binding activities of Oatp2 and Ntcp transactivators were assessed by electrophoretic mobility shift assays.
RESULTS: All basolateral Oatps (1, 2 and 4) were specifically down-regulated at the protein level by 30-40% of controls, but less pronounced than Ntcp (minus 70-80%). In contrast to unaltered Oatp4 mRNA levels, Oatp1 and Oatp2 mRNAs were reduced to various extents (minus 40-90% of controls). Binding activity of known transactivators of Ntcp and Oatp2 such as hepatocyte nuclear factor 1 (HNF1), CAAT enhancer binding protein alpha (C/EBPalpha) and pregnane X receptor (PXR) were also diminished during the time of cholestasis.
CONCLUSIONS: Estrogen-induced cholestasis results in a down-regulation of all basolateral organic anion transporters. The moderate decline in expression of Oatp1, -2 and -4 may explain the unchanged sodium-independent transport of bile acids due to overlapping substrate specificity. Reduction in transporter gene expression seems to be mediated by a diminished nuclear binding activity of transactivators such as HNF1, C/EBP and PXR by estrogens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12507762     DOI: 10.1016/s0005-2736(02)00657-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  19 in total

1.  Inhibition of Na+-taurocholate Co-transporting polypeptide-mediated bile acid transport by cholestatic sulfated progesterone metabolites.

Authors:  Shadi Abu-Hayyeh; Pablo Martinez-Becerra; Siti H Sheikh Abdul Kadir; Clare Selden; Marta R Romero; Myrddin Rees; Hanns-Ulrich Marschall; Jose J G Marin; Catherine Williamson
Journal:  J Biol Chem       Date:  2010-02-20       Impact factor: 5.157

Review 2.  Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug.

Authors:  Hongjian Zhang; Donghui Cui; Bonnie Wang; Yong-Hae Han; Praveen Balimane; Zheng Yang; Michael Sinz; A David Rodrigues
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 3.  Intrahepatic cholestasis of pregnancy.

Authors:  Victoria Geenes; Catherine Williamson
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742

4.  Hepatic pharmacokinetics of taurocholate in the normal and cholestatic rat liver.

Authors:  Daniel Y Hung; Gerhard A Siebert; Ping Chang; Michael S Roberts
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 5.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

6.  ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy.

Authors:  R Müllenbach; A Bennett; N Tetlow; N Patel; G Hamilton; F Cheng; J Chambers; R Howard; S D Taylor-Robinson; C Williamson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 7.  Genetics of familial intrahepatic cholestasis syndromes.

Authors:  S W C van Mil; R H J Houwen; L W J Klomp
Journal:  J Med Genet       Date:  2005-06       Impact factor: 6.318

Review 8.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

9.  Role of AMP-activated protein kinase α1 in 17α-ethinylestradiol-induced cholestasis in rats.

Authors:  Xiaojiaoyang Li; Runping Liu; Lan Luo; Linxi Yu; Xin Chen; Lixin Sun; Tao Wang; Phillip B Hylemon; Huiping Zhou; Zhenzhou Jiang; Luyong Zhang
Journal:  Arch Toxicol       Date:  2016-04-18       Impact factor: 5.153

10.  Hepatic Transporter Expression in Metabolic Syndrome: Phenotype, Serum Metabolic Hormones, and Transcription Factor Expression.

Authors:  Ajay C Donepudi; Qiuqiong Cheng; Zhenqiang James Lu; Nathan J Cherrington; Angela L Slitt
Journal:  Drug Metab Dispos       Date:  2016-02-04       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.